Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.
Dr. Craig Dees, Ph.D., CEO of Provectus said, “We are excited by the positive data reported from both of the Phase 2 clinical trials for PH-10. As previously announced, our development plans include seeking licensure of PH-10 for the treatment of serious dermatological diseases. Based upon these initial results, we are ramping up these efforts, and are actively seeking to engage a financial advisor to assist us with a proposed licensing transaction.”
In its Phase 2 trial of PH-10 for psoriasis, preliminary data shows that 79% of 29 subjects in the clinical trial demonstrated improvement in the Psoriasis Scoring Index (PSI) during four weeks of daily treatment with PH-10. In addition, 83% of the subjects reported no or only mild pruritus (itching) by week four of the trial, with no significant safety issues noted. The 30th and final subject will complete final evaluation in early December.
The study, which involves treatment of 30 subjects with mild-to-moderate plaque psoriasis on the trunk or extremities, was designed to assess the efficacy and safety of topical PH-10 applied once daily to psoriatic plaque areas. The study began in July 2009 and is expected to be completed by December 2009, with final data collection for primary outcome by February 2010.